Inada T, Sugita T, Dobashi I, Inagaki A, Kitao Y, Matsuda G, Kato S, Takano T, Yagi G, Asai M
National Institute of Mental Health, National Center of Neurology and Psychiatry, Chiba, Japan.
Psychiatr Genet. 1995 Fall;5(3):113-6. doi: 10.1097/00041444-199505030-00003.
To investigate the possible effect of polymorphism at the BalI site of the dopamine D3 receptor gene (DRD3) on the phenotype in human subjects, allele and genotype frequencies for this polymorphic site were examined in 113 schizophrenic patients, including six subgroups, and 48 normal controls. The schizophrenic subgroups included patients with early onset, those with a family history, and those who suffered from one of the following psychiatric symptoms at their first episode: (1) delusion and hallucination; (2) disorganization; (3) bizarre behavior; and (4) negative symptoms. No significant differences were observed in genotype, allele and homozygosity frequencies between the whole group or any subgroup of schizophrenic patients and the controls. The present results indicate that polymorphism at the BalI site of the DRD3 is unlikely to be a major contributor to any of the psychiatric parameters examined in the present population of schizophrenic subjects.
为研究多巴胺D3受体基因（DRD3）的BalI位点多态性对人类受试者表型的可能影响，在113例精神分裂症患者（包括六个亚组）和48例正常对照中检测了该多态性位点的等位基因和基因型频率。精神分裂症亚组包括早发患者、有家族史的患者，以及首次发病时出现下列精神症状之一的患者：（1）妄想和幻觉；（2）紊乱；（3）怪异行为；（4）阴性症状。在精神分裂症患者的整个组或任何亚组与对照组之间，基因型、等位基因和纯合子频率均未观察到显著差异。目前的结果表明，DRD3的BalI位点多态性不太可能是本研究中精神分裂症受试者群体所检测的任何精神参数的主要影响因素。
